Frank M. Longo, M.D., Ph.D.
Chairman, Co-founderDr. Longo is Chairman of the Board and Co-founder of PharmatrophiX. Dr. Longo received his MD in 1981 and PhD in Neurosciences in 1983 from UC San Diego. He completed his neurology training in the Department of Neurology at UC San Francisco where he was then recruited as an assistant professor and promoted to professor and vice chair. From 2001 to 2005 he was chair of the Department of Neurology at the University of North Carolina-Chapel Hill and served as chair of the Department of Neurology and Neurological Sciences at Stanford University from 2006-2023. With support from the Alzheimer’s Drug Discovery Foundation, Alzheimer’s Association, Eastern North Carolina Chapter of the Alzheimer’s Association, the NIH-National Institute on Aging and generous donations, he and his team, along with co-inventor Dr. Stephen Massa MD, PhD at UCSF, pioneered the development of small molecules targeting neurotrophin receptors for the treatment of Alzheimer’s, Huntington’s diseases and other disorders. In 2005, while at UNC, he co-founded PharmatrophiX for the focus on commercial development of such compounds. Dr. Longo is the inaugural recipient of the Melvin R. Goodes Prize for Excellence in Alzheimer’s Drug Discovery. Dr. Longo serves in many advisory capacities including the National Advisory Council on Aging, NIH study sections, editorial boards, foundations, grant review boards and therapy evaluations.
Anne Chun Longo
Co‑Founder, Founding CEOAnne Chun Longo is Co-Founder of PharmatrophiX and served as its Founding CEO from 2006 to 2025. She currently serves as Senior Advisor, continuing to advance the company’s mission to develop novel therapeutics for neurodegenerative diseases.
She brings more than 25 years of experience in academic medicine and development, most recently at Stanford University, where she leads strategic initiatives to secure philanthropic funding for innovative clinical programs and translational research in the neurosciences and cancer, raising more than $360 million, including the creation of 14 endowed professorships.
Throughout her career, Ms. Longo has partnered with physician-scientists, institutional leaders, donors, and investors to align funding with high-impact research priorities. She has deep experience bridging philanthropy, academic medicine, and early-stage science—helping translate promising research into funded programs and clinical impact.
At PharmatrophiX, she manages business development, investor relations, and patient advocacy, with a focus on accelerating therapies that address significant unmet needs in neurodegenerative disorders.
She holds a bachelor’s degree from Stanford University.
David Setboun, Pharm.D., MBA
Chief Executive OfficerDavid Setboun, Pharm.D., MBA, is a life sciences CEO with more than 20 years of experience building and scaling biotech and pharmaceutical organizations across neurology, rare disease, oncology, and aging science. He has held senior leadership roles at Eli Lilly, AstraZeneca, and Biogen, where he led initiatives in corporate development, commercial strategy, and global operations, including multiple product launches, portfolio transformations, and strategic partnerships with large pharmaceutical companies and academic centers. As Chief Executive Officer of Pharmatrophix, David leads a clinical‑stage neurodegeneration company advancing first‑in‑class p75 neurotrophin receptor modulators with the potential to change the trajectory of Alzheimer’s disease and rare neurodegenerative disorders, including progressive supranuclear palsy and Huntington’s disease. He oversees the company’s clinical and corporate strategy, including the expansion of its mid‑stage clinical pipeline, global collaborations, and financing activities aimed at bringing disease‑modifying treatments to patients with high unmet medical need.
Louise F. Brady
Board of Directors, Managing Partner, Piedmont CapitalLouise F. Brady has served as a director since October 2023. Ms. Brady is the Co-Founder and Managing Partner of Piedmont Capital Partners, LLC; Piedmont Capital Partners II, LLC; and Piedmont Capital Investments, LLC (collectively with their affiliated entities, “Piedmont Capital”) since 2013, 2019, and 2020, respectively. Piedmont Capital invests in privately held companies focused on transformative and emerging technology. The firm is an active investor in both biotech and the American resilience themes of energy transition and defense.
Ms. Brady currently serves as a Director for both Comcast Corporation and Travel + Leisure (previously Wyndham Worldwide and Wyndham Destinations). She has also served as a Director of various other privately held portfolio companies. Her career and passion center on investing in and supporting entrepreneurial teams with breakthrough science and technology.
She began her career in banking with Bank of America and its predecessors. After a decade, she transitioned into the investment advisory business, serving as Vice President of Investments at Wells Fargo Advisors Financial Services for 20 years. She has also served on many nonprofit boards, including Cone Health, Piedmont Triad Partnership, The Bryan Foundation, shift_ed, and the Shuford Program in Entrepreneurship at the University of North Carolina at Chapel Hill.
She and her husband have three grown children and reside in North Carolina.
Robert B. Sims, M.D.
Board of Directors, Medical LeaderRobert Sims, MD, has been on the Board of Directors at PharmatrophiX since 2017. He is board certified in Internal Medicine, Hematology, and Medical Oncology. He has over 25 years of clinical research experience in the biotech and pharmaceutical industry, including senior roles at Dendreon, Seagen, and Pfizer. He received his medical degree from Oregon Health Sciences University, then completed residency training at NYU in New York and fellowship training at Fox Chase Cancer Center in Philadelphia. Dr. Sims and his wife have three grown sons and reside in the Seattle area. He has also served on the board of Project Access Northwest, a nonprofit that helps coordinate medical and dental care for those in need in the Pacific Northwest.
Jeffrey L. Cummings, M.D., Sc.D.
University of Nevada, Las VegasUNLV research professor Jeffrey L. Cummings is a neurologist globally recognized for his contributions to Alzheimer’s research, drug development, and clinical trials. He serves as the Joy Chambers-Grundy professor of brain science and director of the Chambers-Grundy Center for Transformative Neuroscience at the Kirk Kerkorian School of Medicine’s Department of Brain Health.
Dr. Cummings leads the UNLV Clinical Trials Observatory, the world’s only research observatory devoted exclusively to analyzing the pipeline of Alzheimer’s drugs in clinical trials to better inform drug development decisions. He also heads a biomarker observatory, which captures and categorizes emerging information on blood tests, brain scans, and digital devices related to Alzheimer’s disease.
Prior to joining UNLV in 2019, Dr. Cummings served as founding director of the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas, as well as two UCLA entities — the Mary S. Easton Center for Alzheimer’s Disease Research, and the Deane F. Johnson Center for Neurotherapeutics.
Named a “Rock Star of Science” by Gentleman’s Quarterly, Dr. Cummings — a fellow of the American Academy for the Advancement of Science — has published 43 books and more than 900 peer-reviewed articles on neuropsychiatry, Alzheimer’s disease, and clinical trials.
His numerous recognitions for his scientific and leadership contributions include the American Association of Geriatric Psychiatry’s Distinguished Scientist Award, Melvin R. Goodes Prize for Excellence in Drug Development from the Alzheimer’s Drug Discovery Foundation, Society for Behavioral and Cognitive Neurology’s Lifetime Achievement Award, and the national Alzheimer’s Association’s Bengt Winblad Lifetime Achievement Award. In 2024, he was ranked by ScholarGPS as the world’s top scholar for his lifetime contributions in the areas of dementia and drug development.
Eric M. Reiman, MD
Banner Alzheimer's InstituteDr. Reiman is Executive Director of the Banner Alzheimer’s Institute, Chief Executive Officer of Banner Research, Professor of Psychiatry at the University of Arizona, University Professor of Neuroscience at Arizona State University, Clinical Director of Neurogenomics at the Translational Genomics Research Institute (TGen), and Director of the Arizona Alzheimer’s Consortium. Following his Psychiatry Training at Duke and Washington University, and launched his career in brain imaging research under Marcus Raichle at Washington University in St. Louis. He is a widely recognized leader in brain imaging, brain mapping, genomics, early detection and tracking of Alzheimer’s disease (AD), and the accelerated evaluation of Alzheimer’s prevention therapies. He and his Banner Alzheimer’s Institute colleagues established the Alzheimer’s Prevention Initiative (API) to launch a new era in Alzheimer’s prevention research. Dr. Reiman is an author of more than 400 publications, a principal investigator of six current NIH grants, and a member of the National Advisory Council on Aging (NIA Council). He is a recipient of the Potamkin Prize for his pioneering contributions to the study of preclinical AD and the accelerated evaluation of AD prevention therapies.
Lon S. Schneider, MD, MS
Keck School of Medicine, USCLon Schneider, MD, serves as Director of the USC National Institute on Aging Alzheimer’s Disease Research Center clinical core and the USC State of California Alzheimer’s Disease Center. His advisory roles have included senior scientific advisor at the NIMH, on the American Psychiatric Association Committee for Practice Guidelines in Alzheimer’s and Other Dementia, the World Federation of Societies of Biological Psychiatry Task Force on Dementia. He holds a master’s degree in biometry and epidemiology and is a widely sought expert in clinical trials methods and drug development. His work involves development with novel neuroregenerative disese therapeutics, the science of outcomes assessment, and approaches to modeling and clinical trials simulations. He is an associate editor or editorial board member of several publications, including the Cochrane Dementia and Cognitive Improvement Group, Current Alzheimer Research, BMC-Psychiatry, Alzheimer’s & Dementia, The Lancet Neurology, and Clinical Neuropharmacology among others. He serves as editor-in-chief of Alzheimer’s & Dementia: Translational Research and Clinical Interventions; and has authored numerous papers and chapters.